Omicron变异株病毒学特征: 关键突变、致病性、免疫逃逸

陈玉清; 李金明

doi:10.12290/xhyxzz.2023-0139

Omicron变异株病毒学特征: 关键突变、致病性、免疫逃逸

doi: 10.12290/xhyxzz.2023-0139

陈玉清^{1, 2},
李金明^{1, 2, ,}

1.
北京医院国家老年医学中心国家卫生健康委临床检验中心中国医学科学院老年医学研究院, 北京 100730
2.
国家卫生健康委临床检验中心/北京协和医学院/中国医学科学院, 北京 100730

详细信息

通讯作者:
李金明，E-mail：jmli@nccl.org.cn

中图分类号: R446.5;R51
计量
- 文章访问数: 1198
- HTML全文浏览量: 42
- PDF下载量: 83
- 被引次数: 0
出版历程
- 收稿日期: 2023-03-21
- 录用日期: 2023-05-05
- 网络出版日期: 2023-05-08
- 刊出日期: 2023-09-30

Virological Characteristics of the Omicron Variant: Key Mutations, Pathogenicity, and Immune Escape

CHEN Yuqing^{1, 2},
LI Jinming^{1, 2
, ,}

1.
National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing 100730, China
2.
National Center for Clinical Laboratories, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information

Corresponding author: LI Jinming, E-mail: jmli@nccl.org.cn

摘要

摘要: 新型冠状病毒(severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) Omicron变异株首次在博茨瓦纳被检出, 随后造成了全世界范围内的感染人数激增。截至目前, Omicron是需要关注的SARS-CoV-2变异株中突变数量最多的毒株, 已在整个基因组中发生至少50次突变。Omicron基因组发生的突变赋予病毒一定的适应性优势, 如受体结合域与人类血管紧张素转换酶2受体亲和力增强导致病毒传播能力增强; 与先前变异株相比, 病毒复制能力减弱导致在COVID-19患者中引起的症状相对较轻。此外, 该变异株具有较高的环境稳定性, 部分逃脱了来自疫苗接种或先前感染诱导的宿主免疫反应, 且对大多数治疗性抗体具有较高的耐药性。本文对Omicron变异株的关键突变、病毒学特征、致病性和免疫逃逸能力进行总结, 以期为完善疫情防控策略和公共卫生举措提供科学参考。
- Omicron变异株 /
- 基因突变 /
- 病毒学特征 /
- 致病性 /
- 免疫逃逸 /
- COVID-19
Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant was first detected in Botswana and subsequently led to a worldwide surge in infections. Until now, Omicron and its lineages, the most highly mutated strains among variants of concern (VOC), have contained at least 50 mutations in the entire genome. Mutations give the virus certain adaptive advantages, such as the enhanced affinity between receptor binding domain (RBD) and human angiotensin-converting enzyme 2 (ACE2) receptors leading to enhanced transmission of the virus, and the weakened ability of virus replication leading to mild symptoms in patients with COVID-19. In addition, given its high environmental stability, Omicron can partially escape the host immune response induced by vaccination or prior infection, and is highly resistant tomost therapeutic antibodies.In this paper, key mutations, virological characteristics, pathogenicity, and immune escape of the Omicron variant are summarized, in order to provide scientific reference for coping with the new situation of the pandemic, as well as improving pandemic prevention and control strategy and public health measures.
- Omicron variant /
- mutations /
- virological characteristics /
- pathogenicity /
- immune escape /
- COVID-19
注释:

作者贡献：陈玉清负责资料收集和论文撰写；李金明负责选题设计并审阅定稿。

利益冲突：所有作者均声明不存在利益冲突

HTML全文

参考文献(61)

[1]	World Health Organization. WHO Coronavirus (COVID-19) Dashboard With Vaccination Data[EB/OL].(2023-05-03)[2023-05-05]. https://covid19.who.int/?gclid=CjwKCAiAlNf-.
[2]	World Health Organization. Tracking SARS-CoV-2 variants[EB/OL].(2023-04-27)[2023-05-05]. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
[3]	Vaughan A. Omicron emerges[J]. New Sci, 2021, 252: 7.
[4]	Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness[J]. Nat Rev Microbiol, 2023, 21: 162-177.
[5]	Hirose R, Itoh Y, Ikegaya H, et al. Differences in environmental stability among SARS-CoV-2 variants of concern: Both Omicron BA. 1 and BA. 2 have higher stability[J]. Clin Microbiol Infect, 2022, 28: 1486-1491. doi: 10.1016/j.cmi.2022.05.020
[6]	Hu J, Peng P, Cao X, et al. Increased immune escape of the new SARS-CoV-2 variant of concern Omicron[J]. Cell Mol Immunol, 2022, 19: 293-295. doi: 10.1038/s41423-021-00836-z
[7]	Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic[J]. Lancet, 2021, 398: 2126-2128. doi: 10.1016/S0140-6736(21)02758-6
[8]	Pastorio C, Zech F, Noettger S. Determinants of spike infectivity, processing and neutralization in SARS-CoV-2 Omicron subvariants BA. 1 and BA. 2[J]. Cell Host Microbe, 2022, 30: 1255-1268. doi: 10.1016/j.chom.2022.07.006
[9]	Chen J, Qiu Y, Wang R, et al. Persistent Laplacian projected Omicron BA. 4 and BA. 5 to become new dominating variants[J]. Comput Biol Med, 2022, 151: 106262. doi: 10.1016/j.compbiomed.2022.106262
[10]	Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19[J]. Nat Rev Microbiol, 2021, 19: 141-154. doi: 10.1038/s41579-020-00459-7
[11]	Tian D, Sun Y, Xu H, et al. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant[J]. J Med Virol, 2022, 94: 2376-2383. doi: 10.1002/jmv.27643
[12]	Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B. 1.1.529 leads to widespread escape from neutralizing antibody responses[J]. Cell, 2022, 185: 467-484. e15. doi: 10.1016/j.cell.2021.12.046
[13]	Chen J, Wang R, Gilby NB, et al. Omicron variant (B. 1.1.529): infectivity, vaccine breakthrough, and antibody resistance[J]. J Chem Inf Model, 2022, 62: 412-422. doi: 10.1021/acs.jcim.1c01451
[14]	Chan YA, Zhan SH. The emergence of the spike furin cleavage site in SARS-CoV-2[J]. Mol Biol Evol, 2022, 39: msab327. doi: 10.1093/molbev/msab327
[15]	Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B. 1.1.7 and B. 1.351 variants to neutralizing antibodies[J]. Nat Med, 2021, 27: 917-924. doi: 10.1038/s41591-021-01318-5
[16]	Wang Q, Ye SB, Zhou ZJ, et al. Key mutations in the spike protein of SARS-CoV-2 affecting neutralization resistance and viral internalization[J]. J Med Virol, 2023, 95: e28407. doi: 10.1002/jmv.28407
[17]	Cox MG, Peacock TP, Harvey WT, et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies[J]. Nat Rev Microbiol, 2023, 21: 112-124. doi: 10.1038/s41579-022-00809-7
[18]	Li Q, Nie J, Wu J, et al. SARS-CoV-2 501Y. V2 variants lack higher infectivity but do have immune escape[J]. Cell, 2021, 184: 2362-2371. e9. doi: 10.1016/j.cell.2021.02.042
[19]	Yu J, Collier AY, Rowe M, et al. Neutralization of the SARS-CoV-2 Omicron BA. 1 and BA. 2 variants[J]. N Engl J Med, 2022, 386: 1579-1580. doi: 10.1056/NEJMc2201849
[20]	Rodino KG, Peaper DR, Kelly BJ, et al. Partial ORF1ab gene target failure with Omicron BA. 2.12.1[J]. J Clin Microbiol, 2022, 60: e00600-22.
[21]	Cao Y, Yisimayi A, Jian F, et al. BA. 2.12.1, BA. 4 and BA. 5 escape antibodies elicited by Omicron infection[J]. Nature, 2022, 608: 593-602. doi: 10.1038/s41586-022-04980-y
[22]	Liu C, Lu J, Li P, et al. A Comparative study on epidemiological characteristics, transmissibility, and pathogenicity of three COVID-19 outbreaks caused by different variants[J]. Int J Infect Dis, 2023. doi: 10.1016/j.ijid.2023.01.039.
[23]	Kumar S, Karuppanan K, Subramaniam G. Omicron (BA. 1) and sub-variants (BA. 1.1, BA. 2, and BA. 3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assess-ment[J]. J Med Virol, 2022, 94: 4780-4791. doi: 10.1002/jmv.27927
[24]	Fantini J, Yahi N, Colson P, et al. The puzzling mutational landscape of the SARS-CoV-2-variant Omicron[J]. J Med Virol, 2022, 94: 2019-2025. doi: 10.1002/jmv.27577
[25]	Fantini J, Yahi N, Azzaz F, et al. Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating COVID-19 outbreaks[J]. J Infect, 2021, 83: 197-206. doi: 10.1016/j.jinf.2021.06.001
[26]	Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12.1, BA. 4 and BA. 5[J]. Nature, 2022, 608: 603-608. doi: 10.1038/s41586-022-05053-w
[27]	Benvenuto D, Angeletti S, Giovanetti M, et al. Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy[J]. J Infect, 2020, 81: e24-e27.
[28]	Goldswain H, Dong X, Penrice-Randal R, et al. The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection[J]. Genome Biol, 2023, 24: 47. doi: 10.1186/s13059-023-02881-5
[29]	Wu H, Xing N, Meng K, et al. Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2[J]. Cell Host Microbe, 2021, 29: 1788-1801. e6. doi: 10.1016/j.chom.2021.11.005
[30]	Garcia-Beltran WF, Denis KJS, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant[J]. Cell, 2022, 185: 457-466. e4. doi: 10.1016/j.cell.2021.12.033
[31]	Zhao H, Lu L, Peng Z, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells[J]. Emerg Microbes Infect, 2022, 11: 277-283. doi: 10.1080/22221751.2021.2023329
[32]	Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181: 271-280. e8. doi: 10.1016/j.cell.2020.02.052
[33]	Suzuki R, Yamasoba D, Kimura I, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant[J]. Nature, 2022, 603: 700-705. doi: 10.1038/s41586-022-04462-1
[34]	Shuai H, Chan JFW, Hu B, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B. 1.1.529 Omicron[J]. Nature, 2022, 603: 693-699. doi: 10.1038/s41586-022-04442-5
[35]	Yamasoba D, Kimura I, Nasser H, et al. Virological characteristics of the SARS-CoV-2 Omicron BA. 2 spike[J]. Cell, 2022, 185: 2103-2115. e19. doi: 10.1016/j.cell.2022.04.035
[36]	Ito K, Piantham C, Nishiura H. Estimating relative generation times and relative reproduction numbers of Omicron BA. 1 and BA. 2 with respect to Delta in Denmark[J]. Math Biosci Eng, 2022, 19: 9005-9017. doi: 10.3934/mbe.2022418
[37]	Qassim SH, Chemaitelly H, Ayoub HH, et al. Effects of BA. 1/BA. 2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections[J]. J Travel Med, 2022, 29: taac068. doi: 10.1093/jtm/taac068
[38]	Kimura I, Yamasoba D, Tamura T, et al. Virological characteristics of the SARS-CoV-2 Omicron BA. 2 subvariants, including BA. 4 and BA. 5[J]. Cell, 2022, 185: 3992-4007. e16. doi: 10.1016/j.cell.2022.09.018
[39]	Tegally H, Moir M, Everatt J, et al. Emergence of SARS-CoV-2 omicron lineages BA. 4 and BA. 5 in South Africa[J]. Nat Med, 2022, 28: 1785-1790. doi: 10.1038/s41591-022-01911-2
[40]	Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron(B. 1.1.529) and delta (B. 1.617.2) variants in England: a cohort study[J]. Lancet, 2022, 399: 1303-1312. doi: 10.1016/S0140-6736(22)00462-7
[41]	Bager P, Wohlfahrt J, Bhatt S, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study[J]. Lancet Infect Dis, 2022, 22: 967-976. doi: 10.1016/S1473-3099(22)00154-2
[42]	Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study[J]. Lancet, 2022, 399: 437-446. doi: 10.1016/S0140-6736(22)00017-4
[43]	Wang L, Berger NA, Kaelber DC, et al. Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron[J]. medRxiv[Preprint]. 2022. doi: 10.1101/2021.12.30.21268495.
[44]	Espenhain L, Funk T, Overvad M, et al. Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021[J]. Euro Surveill, 2021, 26: 2101146.
[45]	Goga A, Bekker LG, Garrett N, et al. Breakthrough SARS-CoV-2 infections during periods of delta and omicron predominance, South Africa[J]. Lancet, 2022, 400: 269-271. doi: 10.1016/S0140-6736(22)01190-4
[46]	Lewnard JA, Hong VX, Patel MM, et al. Clinical outcomes associated with SARS-CoV-2 Omicron (B. 1.1.529) variant and BA. 1/BA. 1.1 or BA. 2 subvariant infection in Southern California[J]. Nat Med, 2022, 28: 1933-1943. doi: 10.1038/s41591-022-01887-z
[47]	Davies MA, Morden E, Rosseau P, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA. 4 and BA. 5 compared with previous waves in the Western Cape Province, South Africa[J]. Int J Infect Dis, 2022, 127: 63-68.
[48]	Hui KPY, Ho JCW, Cheung M, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo[J]. Nature, 2022, 603: 715-720. doi: 10.1038/s41586-022-04479-6
[49]	Halfmann PJ, Iida S, Iwatsuki-Horimoto K, et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters[J]. Nature, 2022, 603: 687-692. doi: 10.1038/s41586-022-04441-6
[50]	Christie B. COVID-19: Early studies give hope omicron is milder than other variants[J]. BMJ, 2021, 375: n3144.
[51]	Zhou H, Tada T, Dcosta BM, et al. Neutralization of SARS-CoV-2 Omicron BA. 2 by Therapeutic Monoclonal Antibodies[J]. bioRxiv[Preprint], 2022 Feb 24: 2022.02.15.480166.
[52]	Nutalai R, Zhou D, Tuekprakhon A, et al. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees[J]. Cell, 2022, 185: 2116-2131. e18. doi: 10.1016/j.cell.2022.05.014
[53]	Kurhade C, Zou J, Xia H, et al. Neutralization of Omicron BA. 1, BA. 2, and BA. 3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine[J]. Nat Commun, 2022, 13: 3602. doi: 10.1038/s41467-022-30681-1
[54]	Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost[J]. Emerg Microbes Infect, 2022, 11: 337-343. doi: 10.1080/22221751.2021.2022440
[55]	Dupont L, Snell LB, Graham C, et al. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern[J]. Nat Microbiol, 2021, 6: 1433-1442. doi: 10.1038/s41564-021-00974-0
[56]	Zou J, Kurhade C, Xia H, et al. Cross-neutralization of Omicron BA. 1 against BA. 2 and BA. 3 SARS-CoV-2[J]. Nat Commun, 2022, 13: 2956. doi: 10.1038/s41467-022-30580-5
[57]	Hachmann NP, Miller J, Collier AY, et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA. 2.12.1, BA. 4, and BA. 5[J]. N Engl J Med, 2022, 387: 86-88. doi: 10.1056/NEJMc2206576
[58]	Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19[J]. Nat Rev Immunol, 2021, 21: 382-393. doi: 10.1038/s41577-021-00542-x
[59]	Ohashi H, Hishiki T, Akazawa D, et al. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA. 1 and BA. 2[J]. Antiviral Res, 2022, 205: 105372. doi: 10.1016/j.antiviral.2022.105372
[60]	Imai M, Ito M, Kiso M, et al. Efficacy of Antiviral Agents against Omicron Subvariants BQ. 1.1 and XBB[J]. N Engl J Med, 2023, 388: 89-91.
[61]	Davis-Gardner ME, Lai L, Wali B, et al. Neutralization against BA. 2.75.2, BQ. 1.1, and XBB from mRNA Bivalent Booster[J]. N Engl J Med, 2023, 388: 183-185. doi: 10.1056/NEJMc2214293

施引文献

资源附件(0)

访问统计

点击查看大图

计量

文章访问数: 1198
HTML全文浏览量: 42
PDF下载量: 83
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

地址：	北京市东城区帅府园1号北京协和医院老楼7号楼 3层302室《协和医学杂志》编辑部
电话：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
期刊网站版权所有：	《协和医学杂志》编辑部京ICP备 11002662

留言板

Omicron变异株病毒学特征: 关键突变、致病性、免疫逃逸

doi: 10.12290/xhyxzz.2023-0139

通讯作者:
李金明，E-mail：jmli@nccl.org.cn

计量

Virological Characteristics of the Omicron Variant: Key Mutations, Pathogenicity, and Immune Escape

Corresponding author: LI Jinming, E-mail: jmli@nccl.org.cn

计量

目录

留言板

Omicron变异株病毒学特征: 关键突变、致病性、免疫逃逸

doi: 10.12290/xhyxzz.2023-0139

通讯作者: 李金明，E-mail：jmli@nccl.org.cn

计量

出版历程

Virological Characteristics of the Omicron Variant: Key Mutations, Pathogenicity, and Immune Escape

Corresponding author: LI Jinming, E-mail: jmli@nccl.org.cn

计量

出版历程

目录

通讯作者:
李金明，E-mail：jmli@nccl.org.cn